中药骨康预防非骨水泥型假体周围早期骨丢失

目的:探讨中药骨康对非骨水泥型人工假体周围早期骨量的影响。方法:50例患者随机分为对照组和治疗组,术后1周对照组予以口服钙尔奇D片,治疗组予以骨康1剂/日 钙尔奇D片。连续服用3周,休息2周,5周为1疗程,连续5个疗程。分别于术后7天、3个月、6个月行假体周围骨密度(DEXA)检测。结果:50例病例中,43例获得完整随访。术后3个月、6个月假体周围骨量(ROI1区和ROI7区)对照组与治疗组相比有显著性差异(P<0.01)。结论:中药骨康能减少假体周围早期骨量丢失。

Clinic Study of Gukang of Preventing Early Cementless Periprosthetic Bone Loss

Objective:To explore the early effect of Gukang on the cementless periprosthetic bone density.Methods:fifty patients who had undergone hip arthroplasty were randomized into control group and the Gukang group.After 1 week postoperatively,the patients of the control group received cyclic therapy with caltrate D(1 tablet/time,1 time/day).The patients in the Gukang group received cyclic therapy with Gukang(1dose/day) plus caltrate D(1 tablet/time,1 time/day).The cyclic therapy was intermittent administration.Namely,the medicine was given in a 3-week cycle followed by 2 weeks of rest and repeated every 5 weeks.Periprosthetic bone mineral density(BMD) was measured by dual energy X-ray absorptiometry(DEXA) at 1 week,3 months,and 6 months respectively.Results:43 of 50 patients have completed 6 months'follow-up.The mean periprosthetic BMD change was significantly different in the ROI1 and ROI7 between the two groups(P<0.01 Gukang group vs.control group).Conclusion:Alendronate can reduce early periprosthetic bone loss.